Oncolytics Biotech Inc.
ONC.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.46M | -4.66M | -5.73M | -7.00M | -5.30M |
| Total Depreciation and Amortization | 67.90K | 67.60K | 57.20K | 77.00K | 71.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 589.80K | 659.20K | 750.80K | 212.60K | 90.60K |
| Change in Net Operating Assets | -156.10K | -595.10K | -685.80K | 3.16M | 157.10K |
| Cash from Operations | -3.95M | -4.53M | -5.61M | -3.54M | -4.98M |
| Capital Expenditure | -- | -- | -4.30K | -23.50K | -113.30K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -4.30K | -23.50K | -113.30K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -102.00K | -103.00K | -100.00K | -80.00K | -65.00K |
| Issuance of Common Stock | 6.33M | 6.23M | 3.61M | 287.00K | 2.17M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -852.00K | -235.00K | -169.00K | -380.00K | -131.00K |
| Cash from Financing | 3.88M | 4.10M | 2.39M | -126.80K | 1.44M |
| Foreign Exchange rate Adjustments | -418.50K | -21.60K | 612.20K | -157.60K | 179.80K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -489.30K | -445.20K | -2.61M | -3.85M | -3.47M |